Activators & Inhibitors

AR-42 (also known as OSU-HDAC42), a derivative of hydroxamate-tethered phenylbutyrate is a broad-spectrum deacetylase inhibitor of both histone and non-histone proteins. AR-42 treatment induces histone hyperacetylation and p21WAF/CIP1 overexpression, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells.

AZD2461 is a novel PARP inhibitor with low affinity for than Olaparib. AZD2641 is currently in Phase I clinical studies to treat solid tumors.

AZD2461 is a novel PARP inhibitor with low affinity for than Olaparib. AZD2641 is currently in Phase I clinical studies to treat solid tumors.

BAM7 is a direct and selective activator of BAX with IC50 value of 3.3 µM.

BAM7 is a direct and selective activator of BAX with IC50 value of 3.3 µM.

Belinostat, also known as PXD101, is a novel and potent hydroxamate-type HDAC inhibitor.

Belinostat, also known as PXD101, is a novel and potent hydroxamate-type HDAC inhibitor.

Belinostat, also known as PXD101, is a novel and potent hydroxamate-type HDAC inhibitor.

BMN673 is a potent and selective PARP1/2 inhibitor with Ki of 1.2 and 0.9 nM, respectively.